1
|
Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, Suárez C, Porta C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, George S, Scheffold C, Wang P, Fedorov V, Motzer RJ, Choueiri TK. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open 2024; 9:102994. [PMID: 38642472 PMCID: PMC11046044 DOI: 10.1016/j.esmoop.2024.102994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Revised: 02/07/2024] [Accepted: 03/11/2024] [Indexed: 04/22/2024] Open
Abstract
BACKGROUND Nivolumab plus cabozantinib (NIVO + CABO) was approved for first-line treatment of advanced renal cell carcinoma (aRCC) based on superiority versus sunitinib (SUN) in the phase III CheckMate 9ER trial (18.1 months median survival follow-up per database lock date); efficacy benefit was maintained with an extended 32.9 months of median survival follow-up. We report updated efficacy and safety after 44.0 months of median survival follow-up in intent-to-treat (ITT) patients and additional subgroup analyses, including outcomes by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic risk score. PATIENTS AND METHODS Patients with treatment-naïve aRCC received NIVO 240 mg every 2 weeks plus CABO 40 mg once daily or SUN 50 mg for 4 weeks (6-week cycles), until disease progression/unacceptable toxicity (maximum NIVO treatment, 2 years). Primary endpoint was progression-free survival (PFS) per blinded independent central review (BICR). Secondary endpoints were overall survival (OS), objective response rate (ORR) per BICR, and safety and tolerability. RESULTS Overall, 323 patients were randomised to NIVO + CABO and 328 to SUN. Median PFS was improved with NIVO + CABO versus SUN [16.6 versus 8.4 months; hazard ratio (HR) 0.59; 95% confidence interval (CI) 0.49-0.71]; median OS favoured NIVO + CABO versus SUN (49.5 versus 35.5 months; HR 0.70; 95% CI 0.56-0.87). ORR (95% CI) was higher with NIVO + CABO versus SUN [56% (50% to 62%) versus 28% (23% to 33%)]; 13% versus 5% of patients achieved complete response, and median duration of response was 22.1 months versus 16.1 months, respectively. PFS and OS favoured NIVO + CABO over SUN across intermediate, poor and intermediate/poor IMDC risk subgroups; higher ORR and complete response rates were seen with NIVO + CABO versus SUN regardless of IMDC risk subgroup. Any-grade (grade ≥3) treatment-related adverse events occurred in 97% (67%) versus 93% (55%) of patients treated with NIVO + CABO versus SUN. CONCLUSIONS After extended follow-up, NIVO + CABO maintained survival and response benefits; safety remained consistent with previous follow-ups. These results continue to support NIVO + CABO as a first-line treatment for aRCC. TRIAL REGISTRATION ClinicalTrials.gov, NCT03141177.
Collapse
Affiliation(s)
- T Powles
- Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, London; Royal Free National Health Service Trust, London, UK.
| | - M Burotto
- Bradford Hill Clinical Research Center, Santiago, Chile
| | | | - A B Apolo
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
| | - M T Bourlon
- Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - A Y Shah
- MD Anderson Cancer Center, Houston, USA
| | - C Suárez
- Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - C Porta
- Department of Internal Medicine, University of Pavia, Pavia, Italy
| | - C H Barrios
- Centro de Pesquisa em Oncologia, Hospital São Lucas, PUCRS, Latin American Cooperative Oncology Group, Porto Alegre, Brazil
| | - M Richardet
- Fundación Richardet Longo, Instituto Oncológico de Córdoba, Córdoba, Argentina
| | - H Gurney
- Westmead Hospital and Macquarie University, Westmead and Sydney, Australia
| | - E R Kessler
- Division of Medical Oncology, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, USA
| | - Y Tomita
- Departments of Urology and Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - J Bedke
- Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany
| | - S George
- Roswell Park Comprehensive Cancer Center, Buffalo
| | | | - P Wang
- Bristol Myers Squibb, Princeton
| | | | - R J Motzer
- Memorial Sloan Kettering Cancer Center, New York
| | - T K Choueiri
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston; Brigham and Women's Hospital, Harvard Medical School, Boston, USA
| |
Collapse
|
2
|
Alonso-Alonso S, Vázquez N, Chacón M, Caballero-Sánchez N, Del Olmo-Aguado S, Suárez C, Alfonso-Bartolozzi B, Fernández-Vega-Cueto L, Nagy L, Merayo-Lloves J, Meana A. An effective method for culturing functional human corneal endothelial cells using a xenogeneic free culture medium. Sci Rep 2023; 13:19492. [PMID: 37945668 PMCID: PMC10636196 DOI: 10.1038/s41598-023-46590-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 11/02/2023] [Indexed: 11/12/2023] Open
Abstract
Endothelial dysfunction is a leading cause of corneal blindness in developed countries and the only available treatment is the endothelial transplantation. However, the limited availability of suitable donors remains a significant challenge, driving the exploration of alternative regenerative therapies. Advanced Therapy Medicinal Products show promise but must adhere to strict regulations that prohibit the use of animal-derived substances. This study investigates a novel culture methodology using Plasma Rich in Growth Factors (PRGF) as the only source of growth factors for primary cultures of human corneal endothelial cells (CECs). CECs were obtained from discarded corneas or endothelial rings and cultured in two different media: one supplemented with xenogeneic factors and other xenogeneic-free, using PRGF. Comprehensive characterization through immunofluorescence, morphological analyses, trans-endothelial electrical resistance measurements, RNA-seq, and qPCR was conducted on the two groups. Results demonstrate that CECs cultured in the xenogeneic-free medium exhibit comparable gene expression, morphology, and functionality to those cultured in the xenogeneic medium. Notably, PRGF-expanded CECs share 46.9% of the gene expression profile with native endothelium and express all studied endothelial markers. In conclusion, PRGF provides an effective source of xenogeneic-free growth factors for the culture of CECs from discarded corneal tissue. Further studies will be necessary to demonstrate the applicability of these cultures to cell therapies that make clinical translation possible.
Collapse
Affiliation(s)
- S Alonso-Alonso
- Instituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avenida del Hospital Universitario, 33011, Oviedo, Asturias, Spain
| | - N Vázquez
- Instituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain.
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avenida del Hospital Universitario, 33011, Oviedo, Asturias, Spain.
| | - M Chacón
- Instituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avenida del Hospital Universitario, 33011, Oviedo, Asturias, Spain
| | - N Caballero-Sánchez
- Doctoral School of Molecular Cell and Immunobiology. Faculty of Medicine, University of Debrecen, Nagyerdei Krt, Debrecen, 4032, Hungary
- Department of Biochemistry and Molecular Biology, Nuclear Receptor Research Laboratory, Faculty of Medicine, University of Debrecen, Nagyerdei Krt, Debrecen, 4032, Hungary
| | - S Del Olmo-Aguado
- Instituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avenida del Hospital Universitario, 33011, Oviedo, Asturias, Spain
| | - C Suárez
- Instituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avenida del Hospital Universitario, 33011, Oviedo, Asturias, Spain
| | - B Alfonso-Bartolozzi
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avenida del Hospital Universitario, 33011, Oviedo, Asturias, Spain
- Instituto Oftalmológico Fernández-Vega. Avenida Doctores Fernández-Vega, 33012, Oviedo, Asturias, Spain
| | - L Fernández-Vega-Cueto
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avenida del Hospital Universitario, 33011, Oviedo, Asturias, Spain
- Instituto Oftalmológico Fernández-Vega. Avenida Doctores Fernández-Vega, 33012, Oviedo, Asturias, Spain
| | - L Nagy
- Department of Biochemistry and Molecular Biology, Nuclear Receptor Research Laboratory, Faculty of Medicine, University of Debrecen, Nagyerdei Krt, Debrecen, 4032, Hungary
- Department of Medicine and Biological Chemistry, Johns Hopkins University School of Medicine, and Institute for Fundamental Biomedical Research, Johns Hopkins All Children's Hospital, 6Th Ave S, St. Petersburg, FL, 33701, USA
| | - J Merayo-Lloves
- Instituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avenida del Hospital Universitario, 33011, Oviedo, Asturias, Spain
| | - A Meana
- Instituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avenida del Hospital Universitario, 33011, Oviedo, Asturias, Spain
- Unidad de Ingeniería Tisular, Centro Comunitario Sangre y Tejidos de Asturias (CCST), Unidad 714 CIBERER, Calle Emilio Rodríguez Vigil, 33006, Oviedo, Asturias, Spain
| |
Collapse
|
3
|
Barrera C, Coloma A, Sinues B, Moreno M, Pinazo I, Gómez-Acebo M, Herranz L, Jiménez M, Suárez C, Garrido P, Fernández-Arjona M. Female urethroplasty for the treatment of urethral stricture, which surgical option to choose? About two cases: oral mucosal graft and vaginal mucosal flap. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02071-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
4
|
Bex A, Uzzo R, Karam J, Master V, Donskov F, Suárez C, Albiges L, Rini B, Tomita Y, Kann A, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Pal S. LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Powles T, Albiges L, Bex A, Grünwald V, Porta C, Procopio G, Schmidinger M, Suárez C, de Velasco G. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol 2021; 32:1511-1519. [PMID: 34597799 DOI: 10.1016/j.annonc.2021.09.014] [Citation(s) in RCA: 90] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 09/13/2021] [Accepted: 09/14/2021] [Indexed: 01/05/2023] Open
Affiliation(s)
- T Powles
- Barts Cancer Institute, Queen Mary University of London, London, UK
| | - L Albiges
- Medical Oncology Department, Gustave Roussy Institute, Villejuif, France
| | - A Bex
- Division of Surgery and Interventional Science, The Royal Free London NHS Foundation Trust and UCL, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - V Grünwald
- Clinic for Internal Medicine (Tumour Research) and Clinic for Urology, West German Cancer Center, University Hospital Essen, Essen, Germany
| | - C Porta
- Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy; Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy
| | - G Procopio
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Schmidinger
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - C Suárez
- Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - G de Velasco
- Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
| |
Collapse
|
6
|
Gabriel R, Muñiz J, Vega S, Moral I, Pérez Castro TR, Rodriguez-Salvanés F, Suárez C, Novella B, Brotons C. Cardiovascular risk in the elderly population of Spain. The EPICARDIAN risk score. Rev Clin Esp 2021; 222:13-21. [PMID: 34565710 DOI: 10.1016/j.rceng.2021.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 05/01/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND AND OBJECTIVES Cardiovascular risk estimation in people over 70 years of age is problematic. Most scores have been created based on cohorts of middle-aged people, with an underrepresentation of older adults. The predictive power of classical cardiovascular risk factors declines with age. The aim of this work is to develop a specific score for estimating cardiovascular risk among the elderly population in Spain. METHODS This work is a population-based cohort established in 1995. SETTING Three geographical areas of Spain (Madrid, Ávila, and Lugo). PARTICIPANTS 3,729 people older than 64 years with no cardiovascular diseases (CVD) at baseline. MEASUREMENTS Suspected fatal and nonfatal CVD (both coronary heart disease and stroke) were investigated annually and confirmed using the WHO-MONICA criteria. All participants were followed-up on until occurrence of a first CVD event, until death, or until December 31, 2015. RESULTS Age was the strongest predictor of CVD at 10 years in both men and women. In men, variables associated with CVD were high blood pressure treatment (HR: 1.35; 95% CI: 1.067-1.710), diabetes (HR: 1.359; 95% CI: 0.997-1.852), and smoking (HR: 1.207; 95% CI: 0.945-1.541) and in women, the variables were smoking (HR: 1.881; 95% CI: 1.356-2.609) and diabetes (HR: 1.285; 95% CI: 0.967-1.707). Total cholesterol did not increase the risk of CVD in men or women. However, total cholesterol levels >200 mg/dL were inversely associated with 10-year risk of CVD in men and women. CONCLUSIONS In elderly Spanish men, total CVD at 10 years is significantly increased by age, diabetes, and antihypertensive treatment and in elderly Spanish women by diabetes and smoking. Total cholesterol levels did not increase the risk of CVD, particularly in males.
Collapse
Affiliation(s)
- R Gabriel
- Departamento de Salud Internacional, Escuela Nacional de Sanidad, Instituto de Salud Carlos III, Madrid, Spain.
| | - J Muñiz
- Instituto Universitario de Ciencias de la Salud, Universidad de La Coruña, A Coruña, Spain
| | - S Vega
- Centro de Salud de Arévalo, SACyL, Arévalo, Ávila, Spain
| | - I Moral
- Unidad de Investigación, EAP Sardenya-IIB, Barcelona, Spain
| | - T R Pérez Castro
- Instituto Universitario de Ciencias de la Salud, Universidad de La Coruña, A Coruña, Spain
| | - F Rodriguez-Salvanés
- Instituto de Investigación Sanitaria Hospital Universitario de La Princesa, Madrid, Spain
| | - C Suárez
- Instituto de Investigación Sanitaria Hospital Universitario de La Princesa, Madrid, Spain
| | - B Novella
- Instituto de Investigación Sanitaria Hospital Universitario de La Princesa, Madrid, Spain
| | - C Brotons
- Unidad de Investigación, EAP Sardenya-IIB, Barcelona, Spain
| | | |
Collapse
|
7
|
de Vries-Brilland M, McDermott DF, Suárez C, Powles T, Gross-Goupil M, Ravaud A, Flippot R, Escudier B, Albigès L. Checkpoint inhibitors in metastatic papillary renal cell carcinoma. Cancer Treat Rev 2021; 99:102228. [PMID: 34111642 DOI: 10.1016/j.ctrv.2021.102228] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 05/13/2021] [Accepted: 05/17/2021] [Indexed: 02/02/2023]
Abstract
Papillary Renal Cell Carcinoma (pRCC) is the most common non-clear cell RCC (nccRCC) and a distinct entity, although heterogenous, associated with poor outcomes. The treatment landscape of metastatic pRCC (mpRCC) relied so far on targeted therapies, mimicking previous developments in metastatic clear-cell renal cell carcinoma. However, antiangiogenics as well as mTOR inhibitors retain only limited activity in mpRCC. As development of immune checkpoint inhibitors (ICI) is now underway in patients with mpRCC, we aimed at discussing early activity data and potential for future therapeutic strategies in monotherapy or combination. Expression of immune checkpoints such as PD-L1 and infiltrative immune cells in pRCC could provide insights into their potential immunogenicity, although this is currently poorly described. Based on retrospective and prospective data, efficacy of ICI as single agent remains limited. Combinations with tyrosine-kinase inhibitors, notably with anti-MET inhibitors, harbor promising response rates and may enter the standard of care in untreated patients. Collaborative work is needed to refine the molecular and immune landscape of pRCC, and pursue efforts to set up predictive biomarker-driven clinical trials in these rare tumors.
Collapse
Affiliation(s)
- M de Vries-Brilland
- Department of Medical Oncology, Integrated Centers of Oncology (ICO) Paul Papin, Angers, France
| | - D F McDermott
- Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - C Suárez
- Medical Oncology, Vall d́Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d́Hebron, Vall d́Hebron Barcelona Hospital Campus, Spain
| | - T Powles
- The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK
| | - M Gross-Goupil
- Department of Medical Oncology, Hôpital Saint-André, University of Bordeaux-CHU, Bordeaux, France
| | - A Ravaud
- Department of Medical Oncology, Hôpital Saint-André, University of Bordeaux-CHU, Bordeaux, France
| | - R Flippot
- Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - B Escudier
- Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - L Albigès
- Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
| |
Collapse
|
8
|
Aparicio P, Barba R, Moldenhauer F, Suárez C, Real de Asúa D. Characteristics of adults with Down syndrome hospitalised in Spanish internal medicine departments during 2005-2014. Rev Clin Esp 2020; 220:553-560. [PMID: 31837747 DOI: 10.1016/j.rce.2019.11.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Revised: 10/18/2019] [Accepted: 11/09/2019] [Indexed: 12/21/2022]
Abstract
INTRODUCTION AND OBJECTIVES The clinical problems of adults with Down syndrome seem to differ from those of the general population. To better understand these differences, we list the demographic and clinical characteristics of adults with Down syndrome admitted to Spanish internal medicine departments during 2005-2014. PATIENTS AND METHODS We conducted an observational retrospective study using data collected from the minimum basic data set on hospitalisation episodes of adults with Down syndrome in the internal medicine departments of Spain's National Health System from 2005 to 2014. We analysed the patients' epidemiological, clinical and societal data. RESULTS A total of 7548 hospitalisation episodes from 3786 patients were recorded. Some 56.6% of the patients were male with a mean age (±SD) of 47±13 years, and 715 of the patients died (18.9%). The age-adjusted mortality was 26.6%, and the mean stay was 9.6±12 days. The hospitalisation was for respiratory disease in 3684 episodes (48.8%) and for cardiac origin in 760 (10%). The most common comorbidities were hypothyroidism (27.1%, 2043 episodes), epilepsy (24.1%, 1819 episodes) and dementia (15.4%, 1162 episodes). CONCLUSIONS The hospitalisation of adults with Down syndrome in internal medicine departments has increased in the past decade. Although the reasons for hospitalisation, mean stay and cost per episode for this population are similar to those of the general population treated by internal medicine departments, the age-adjusted hospital mortality was significantly greater.
Collapse
Affiliation(s)
- P Aparicio
- Servicio de Medicina Interna, Hospital Universitario Clínico San Carlos, Madrid, España.
| | - R Barba
- Servicio de Medicina Interna, Hospital Universitario Rey Juan Carlos, Móstoles (Madrid), España; Grupo de Trabajo de Gestión Clínica, Sociedad Española de Medicina Interna, Madrid, España; Universidad Rey Juan Carlos, Móstoles (Madrid), España
| | - F Moldenhauer
- Servicio de Medicina Interna, Hospital Universitario de la Princesa, Madrid, España; Universidad Autónoma de Madrid, Madrid, España
| | - C Suárez
- Servicio de Medicina Interna, Hospital Universitario de la Princesa, Madrid, España; Universidad Autónoma de Madrid, Madrid, España
| | - D Real de Asúa
- Servicio de Medicina Interna, Hospital Universitario de la Princesa, Madrid, España; Division of Medical Ethics, Department of Medicine, Weill Cornell Medicine, Nueva York, Estados Unidos
| |
Collapse
|
9
|
Aparicio P, Barba R, Moldenhauer F, Suárez C, Real de Asúa D. Characteristics of adults with Down syndrome hospitalized in Spanish internal medicine departments during 2005–2014. Rev Clin Esp 2020. [DOI: 10.1016/j.rceng.2019.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Maldonado J, Morales Barrera R, Vidal N, Feltes N, Domenech M, Puente J, Figols M, González M, Lozano F, López H, Gallardo E, Moreno D, Suárez C, Morote J, Carles J, Giralt J. PO-1210: Local treatment on the outcome of immunecheckpoint inhibitors in metastatic urothelial carcinoma. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01228-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Jimenez N, Reig O, Castellano G, Orrillo M, Ferrer-Mileo L, Oberoi H, Pesántez D, Font A, Domènech M, Rodríguez-Vida A, Carles J, Suárez C, Sala-González N, Rodríguez-Carunchio L, Díaz S, Prat A, Marín-Aguilera M, Mellado B. 1971P Neuroendocrine (NE) expression profiling in non-castrate tumours is associated with poor therapy benefit and adverse clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
12
|
Lázaro M, Valderrama BP, Suárez C, de-Velasco G, Beato C, Chirivella I, González-del-Alba A, Laínez N, Méndez-Vidal MJ, Arranz JA. SEOM clinical guideline for treatment of kidney cancer (2019). Clin Transl Oncol 2020; 22:256-269. [DOI: 10.1007/s12094-019-02285-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2019] [Accepted: 12/26/2019] [Indexed: 12/18/2022]
Abstract
AbstractIn this article, we review de state of the art on the management of renal cell carcinoma (RCC) and provide recommendations on diagnosis and treatment. Recent advances in molecular biology have allowed the subclassification of renal tumours into different histologic variants and may help to identify future prognostic and predictive factors. For patients with localized disease, surgery is the treatment of choice with nephron-sparing surgery recommended when feasible. No adjuvant therapy has demonstrated a clear benefit in overall survival. Considering the whole population of patients with advanced disease, the combination of axitinib with either pembrolizumab or avelumab increase response rate and progression-free survival, compared to sunitinib, but a longer overall survival has only been demonstrated so far with the pembrolizumab combo. For patients with IMDC intermediate and poor prognosis, nephrectomy should not be considered mandatory. In this subpopulation, the combination of ipilimumab and nivolumab has also demonstrated a superior response rate and overall survival vs. sunitinib. In patients progressing to one or two antiangiogenic tyrosine-kinase inhibitors, both nivolumab and cabozantinib in monotherapy have shown benefit in overall survival compared to everolimus. Although no clear sequence can be recommended, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in patients with metastatic RCC.
Collapse
|
13
|
Nixon IJ, Shah JP, Zafereo M, Simo RS, Hay ID, Suárez C, Zbären P, Rinaldo A, Sanabria A, Silver C, Mäkitie A, Vander Poorten V, Kowalski LP, Shaha AR, Randolph GW, Ferlito A. The role of radioactive iodine in the management of patients with differentiated thyroid cancer - An oncologic surgical perspective. Eur J Surg Oncol 2020; 46:754-762. [PMID: 31952928 DOI: 10.1016/j.ejso.2020.01.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Revised: 11/16/2019] [Accepted: 01/06/2020] [Indexed: 12/18/2022] Open
Abstract
With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a "one-size-fits-all" recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. This review considers the evidence base for the benefits of using RAI in the primary and recurrent setting as well as the side-effects and risks from RAI treatment. By considering the pros and cons of adjuvant therapy we present an oncologic surgical perspective on selection of treatment for patients, both following pre-operative diagnostic biopsy and in the setting of a post-operative diagnosis of malignancy.
Collapse
Affiliation(s)
- I J Nixon
- Department of Otolaryngology, Head and Neck Surgery, NHS Lothian, University of Edinburgh, UK.
| | - J P Shah
- Head and Neck Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - M Zafereo
- Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA
| | - R S Simo
- Department of Otorhinolaryngology Head and Neck Surgery, Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK
| | - I D Hay
- Division of Endocrinology and Internal Medicine, Mayo Clinic School of Medicine, Rochester, MN, USA
| | - C Suárez
- Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain; Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain
| | - P Zbären
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Bern, Switzerland
| | - A Rinaldo
- University of Udine School of Medicine, Udine, Italy
| | - A Sanabria
- Department of Surgery, School of Medicine, Universidad de Antioquia, Centro de Excelencia en Cirugia de Cabeza y Cuello-CEXCA, Medellin, Colombia
| | - C Silver
- Department of Surgery, University of Arizona College of Medicine, Phoenix, AZ, USA
| | - A Mäkitie
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Finland; Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute and Karolinska Hospital, Stockholm, Sweden
| | - V Vander Poorten
- Department of Oncology, section Head and Neck Oncology, KU Leuven, and Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium
| | - L P Kowalski
- Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center, and Head and Neck Surgery Department, Faculty of Medicine, University of Sao Paulo, São Paulo, Brazil
| | - A R Shaha
- Head and Neck Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - G W Randolph
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA
| | - A Ferlito
- Coordinator of the International Head and Neck Scientific Group, Padua, Italy
| |
Collapse
|
14
|
Requena Calleja M, Arenas Miquélez A, Díez-Manglano J, Gullón A, Pose A, Formiga F, Mostaza J, Cepeda J, Suárez C. Sarcopenia, frailty, cognitive impairment and mortality in elderly patients with non-valvular atrial fibrillation. Rev Clin Esp 2019. [DOI: 10.1016/j.rceng.2019.04.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Jimenez N, Reig O, Montalbo R, Milà-Guasch M, Nadal-Dieste L, Victoria I, Font A, Rodriguez-Vida A, Carles J, Suárez C, Domenech M, Sala-González N, Fernández P, Prat A, Marín-Aguilera M, Mellado B. Cell plasticity and taxanes resistance in metastatic prostate cancer: ESRP1 as a predictive biomarker of taxane response. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz268.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Suárez C, Lee JL, Ziobro M, Gafanov R, Matveev V, Donskov F, Pouliot F, Alekseev B, Wiechno P, Tomczak P, Climent M, Shin S, Kloss Silverman R, Perini R, Schloss C, McDermott D, Atkins M. First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.044] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Morales Barrera R, Matos I, Gonzalez M, Suárez C, Ros J, Valverde C, Fernandez C, Hierro C, Serra E, Mateo J, Gutierrez S, Martín Liberal J, Quintana A, Dienstmann R, Serrano C, Garralda E, Carles J. Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Ligero M, Garcia-Ruiz A, Viaplana C, Raciti M, Matos I, Liberal JM, Hierro C, Gonzalez M, Barrera RM, Suárez C, Elez E, Brana I, Muñoz-Couselo E, Oaknin A, Felip E, Tabernero J, Carles J, Dienstmann R, Garralda E, Lopez RP. Artificial intelligence combining radiomics and clinical data for predicting response to immunotherapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I, García-Del-Muro X, González-Del-Alba A, Grande E, Suárez C. Correction to: SEOM clinical guideline for treatment of kidney cancer (2017). Clin Transl Oncol 2019; 21:692-693. [PMID: 30798511 DOI: 10.1007/s12094-019-02058-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The conflict of interest declaration was published incorrectly in the original version.
Collapse
Affiliation(s)
- E Gallardo
- Medical Oncology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Parc Taulí, 1, 08208, Sabadell, Spain
| | - M J Méndez-Vidal
- Medical Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Córdoba, Spain
| | - J L Pérez-Gracia
- Medical Oncology Department, Clinica Universidad de Navarra, Pamplona, Spain
| | | | - M Campayo
- Medical Oncology Department, Hospital Universitari Mutua Terrassa, Terrassa, Spain
| | - I Chirivella-González
- Medical Oncology Department, Hospital Clínico, Universidad de Valencia, Valencia, Spain
| | - X García-Del-Muro
- Medical Oncology Department, Institut Catala d'Oncologia, Idibell, Universitat de Barcelona, Barcelona, L'Hospitalet de Llobregat, Spain
| | - A González-Del-Alba
- Oncology Department, Hospital Universitario Son Espases, Palma De Mallorca, Spain
| | - E Grande
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - C Suárez
- Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.
| |
Collapse
|
20
|
García I, Vizoso F, Suárez C, Sanz L, Rodríguez J, Roiz C, García-Muñiz J. Relationship of Tumoral Hyaluronic Acid and Cathepsin D Contents with Histological Type of Gastric Carcinoma. Int J Biol Markers 2018. [DOI: 10.1177/172460080001500302] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The aim of this work was to evaluate the cytosolic contents of hyaluronic acid (HA) and cathepsin D (CatD) in gastric carcinomas and their possible relationships with the clinicopathological parameters of the tumors. Our study demonstrated a wide variability in the cytosolic levels of HA (mean ± SEM: 3748 ± 411 ng/mg protein) and cathepsin D (52 ± 4 pmol/mg protein) in the tumors of 78 gastric cancer patients. In addition, the tumoral contents of HA and CatD were significantly higher (p<0.005) in diffuse type (HA: 6027 ± 1099 ng/mg protein; CatD: 75 ± 13 pmol/mg protein) than in intestinal type (HA: 2735 ± 242 ng/mg protein; CatD: 42±3 pmol/mg protein) carcinomas. These data suggest that both markers may contribute to the biological characterization of gastric carcinomas.
Collapse
Affiliation(s)
- I. García
- Servicio de Cirugía General, Hospital Central de Asturias, Oviedo
| | - F. Vizoso
- Servicio de Cirugía General, Hospital de Jove, Gijón
| | - C. Suárez
- Servicio de Cirugía General, Hospital Central de Asturias, Oviedo
| | - L. Sanz
- Servicio de Cirugía General, Hospital de Jove, Gijón
| | | | - C. Roiz
- Servicio de Medicina Nuclear, Hospital Central de Asturias, Oviedo - Spain
| | | |
Collapse
|
21
|
Suárez C, Vizoso F, Rodríguez JC, García I, Raigoso P, Allende MT, García-Muñíz JL, García-Morán M. Prognostic Significance of Cytosolic pS2 Protein Content in Gastric Cancer. Int J Biol Markers 2018; 16:37-44. [PMID: 11288953 DOI: 10.1177/172460080101600105] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
pS2, a 60-amino-acid chain peptide which is the most widespread estrogen-induced RNA messenger in MCF-7 breast cancer cells, is normally detected in the epithelium of gastric mucosa. The aims of this work were to evaluate the cytosolic pS2 content and its clinical significance in gastric carcinomas. Cytosolic pS2 levels were examined by immunoradiometric methods in 108 patients with primary gastric adenocarcinomas. The mean follow-up period was 23.3 months. The cytosolic pS2 levels of the tumors ranged widely, i.e., from 0.1 to 3217 ng/mg protein. There were no significant differences in pS2 content between tumors (mean ± standard error: 137.2±31.4 ng/mg protein) and paired adjacent mucosa samples (n=84; mean ± standard error: 249.6±32.6 ng/mg protein), nor were there any significant differences in tumoral pS2 levels with respect to clinicopathologic parameters such as patient age and sex or tumor location, stage, histologic type or grade. However, the results indicated that high intratumoral pS2 levels were significantly and independently associated with an unfavorable outcome in the overall group of patients (p=0.0266) and in patients with resectable gastric cancer (p=0.003). In conclusion, pS2 may represent a useful biological marker in gastric cancer.
Collapse
Affiliation(s)
- C Suárez
- Department of General Surgery, Hospital de Jove, Gijón, Spain
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Bex A, Pal S, Rini B, Albiges L, Suárez C, Donaldson F, Qiu J, Hashimoto K, Uzzo R. A phase III study of atezolizumab vs placebo as adjuvant therapy in patients with renal cell carcinoma at high risk of recurrence following resection (IMmotion010). ACTA ACUST UNITED AC 2018. [DOI: 10.1016/s1569-9056(18)31645-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
23
|
Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I, García-del-Muro X, González-del-Alba A, Grande E, Suárez C. SEOM clinical guideline for treatment of kidney cancer (2017). Clin Transl Oncol 2018; 20:47-56. [PMID: 29134564 PMCID: PMC5785618 DOI: 10.1007/s12094-017-1765-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Accepted: 10/06/2017] [Indexed: 01/05/2023]
Abstract
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.
Collapse
Affiliation(s)
- E. Gallardo
- Medical Oncology Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Parc Taulí, 1, 08208 Sabadell, Spain
| | - M. J. Méndez-Vidal
- Medical Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Córdoba, Spain
| | - J. L. Pérez-Gracia
- Medical Oncology Department, Clinica Universidad de Navarra, Pamplona, Spain
| | | | - M. Campayo
- Medical Oncology Department, Hospital Universitari Mutua Terrassa, Terrassa, Spain
| | | | - X. García-del-Muro
- Medical Oncology Department, Institut Catala d’Oncologia, Idibell, Universitat de Barcelona, Barcelona, L’Hospitalet de Llobregat Spain
| | - A. González-del-Alba
- Oncology Department, Hospital Universitario Son Espases, Palma De Mallorca, Spain
| | - E. Grande
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - C. Suárez
- Medical Oncology Department, Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
24
|
Marino M, Olaiz N, Signori E, Maglietti F, Suárez C, Michinski S, Marshall G. pH fronts and tissue natural buffer interaction in gene electrotransfer protocols. Electrochim Acta 2017. [DOI: 10.1016/j.electacta.2017.09.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
25
|
Marín-Aguilera M, Reig O, Font A, Rodríguez-Vida A, Suárez C, Domenech M, Jiménez N, Victoria I, López S, Milà-Guasch M, Felip E, Etxaniz O, Carles J, Racca F, Sala-González N, González del Alba A, Fernández P, Prat A, Mellado B. Ability of TMPRSS2-ERG (TE) expression to predict taxane benefit depending on prior abiraterone or enzalutamide therapy in castration-resistant prostate cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx390.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Hyman D, Chatterjee M, Langenberg M, Lin C, Suárez C, Tai D, Cassier P, Yamamoto N, De Weger V, Jeay S, Meille C, Halilovic E, Mariconti L, Guerreiro N, Kumar A, Wuerthner J, Bauer S. Dose- and regimen-finding phase I study of NVP-HDM201 in patients (pts) with TP53 wild-type (wt) advanced tumors. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32982-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
27
|
Rovedo C, Suárez C, Viollaz P. Kinetics of forced convective air drying of potato and squash slabs / Cinética del secado de rodajas de patatas y calabacin con corriente de aire. FOOD SCI TECHNOL INT 2016. [DOI: 10.1177/108201329700300403] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Moisture content, temperature, and surface area variations of potato and squash slabs were measured during forced convective air drying; the effect of the initial moisture content on drying behaviour was also investigated. A mathematical model that numerically integrated the diffusion equation and the thermal balance for a three-dimensional shrinking slab was used to simulate the drying process. The parameters of the model (surface area, heat transfer coefficient and dry solid density) were experimentally determined. Fitting parameters (activation energy and pre- exponential coefficient in the Arrhenius equation) were found by comparing experimental and predicted drying curves. Good agreement was obtained down to a moisture level of 0.4 kg water/kg dry solid. Diffusion coefficients were independent of their moisture content within the range studied for both products. The activation energies for potato and squash were 2.09 x 104 kJ/kg mol and 3.76 x 10 4 kJ/kg mol, respectively. Changes in the rates of drying and heating curves for potato took place at moisture levels around 0.4 kg water/kg dry solid, but this was not the case for squash. The differences were mainly attributed to the different shapes of the sorp tion isotherms.
Collapse
Affiliation(s)
- C.O. Rovedo
- Departamento de industrias. Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires. Ciudad Universitaria 1428 Buenos Aires, Argentina
| | - C. Suárez
- Departamento de industrias. Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires. Ciudad Universitaria 1428 Buenos Aires, Argentina
| | - P.E. Viollaz
- Departamento de industrias. Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires. Ciudad Universitaria 1428 Buenos Aires, Argentina
| |
Collapse
|
28
|
Nixon IJ, Suárez C, Simo R, Sanabria A, Angelos P, Rinaldo A, Rodrigo JP, Kowalski LP, Hartl DM, Hinni ML, Shah JP, Ferlito A. The impact of family history on non-medullary thyroid cancer. Eur J Surg Oncol 2016; 42:1455-63. [PMID: 27561845 DOI: 10.1016/j.ejso.2016.08.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Revised: 07/03/2016] [Accepted: 08/04/2016] [Indexed: 10/21/2022] Open
Abstract
INTRODUCTION Around 10% of patients with non-medullary thyroid cancer (NMTC) will have a positive family history for the disease. Although many will be sporadic, families where 3 first-degree relatives are affected can be considered to represent true familial non-medullary thyroid cancer (FNMTC). The genetic basis, impact on clinical and pathological features, and overall effect on prognosis are poorly understood. METHODS A literature review identified articles which report on genetic, clinical, therapeutic and screening aspects of FNMTC. The results are presented to allow an understanding of the genetic basis and the impact on clinical-pathological features and prognosis in order to inform clinical decision making. RESULTS The genetic basis of FNMTC is unknown. Despite this, significant progress has been made in identifying potential susceptibility genes. The lack of a test for FNMTC has led to a clinical definition requiring a minimum of 3 first-degree relatives to be diagnosed with NMTC. Although some have shown an association with multi-centric disease, younger age and increased rates of extra-thyroidal extension and nodal metastases, these findings are not supported by all. The impact of FNMTC is unclear with all groups reporting good outcome, and some finding an association with more aggressive disease. The role of screening remains controversial. CONCLUSION FNMTC is rare but can be diagnosed clinically. Its impact on prognostic factors and the subsequent role in influencing management is debated. For those patients who present with otherwise low-risk differentiated thyroid cancer, FNMTC should be included in risk assessment when discussing therapeutic options.
Collapse
Affiliation(s)
- I J Nixon
- Department of ENT/Head and Neck Surgery, NHS Lothian, Edinburgh University, UK; Department of Otolaryngology, Head and Neck Surgery, NHS Lothian, Edinburgh University, UK.
| | - C Suárez
- Department of Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain; Fundación de Investigación e Innovación Biosanitaria del Principado de Asturias, Oviedo, Spain
| | - R Simo
- Head and Neck Cancer Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK
| | - A Sanabria
- Department of Surgery, School of Medicine, Universidad de Antioquia, Fundación Colombiana de Cancerología - Clínica Vida, Medellin, Colombia
| | - P Angelos
- Department of Surgery and Surgical Ethics, The University of Chicago Medicine, Chicago, IL, USA
| | - A Rinaldo
- University of Udine School of Medicine, Udine, Italy
| | - J P Rodrigo
- Department of Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, Oviedo, Spain
| | - L P Kowalski
- Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center, Sao Paulo, SP, Brazil
| | - D M Hartl
- Department of Otolaryngology-Head and Neck Surgery, Institut Gustave Roussy, Villejuif Cedex, France; Laboratoire de Phonétique et de Phonologie, Sorbonne Nouvelle, Paris, France
| | - M L Hinni
- Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Phoenix, AZ, USA
| | - J P Shah
- Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - A Ferlito
- Department of Surgical Sciences, ENT Clinic, University of Udine School of Medicine, Udine; International Head and Neck Scientific Group, Italy
| |
Collapse
|
29
|
Torre-Alonso J, Carmona L, Moreno M, Galíndez E, Babío J, Zarco P, Linares L, Collantes E, Fernández-Barrial M, Hermosa J, Coto P, Suárez C, Almodόvar R, Luelmo J, Cárcaba V, Castañeda S, Gratacόs J. FRI0457 Recommendations for The Management of Comorbidities in Psoriatic Disease: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Carmona L, Torre-Alonso J, Moreno M, Galíndez E, Babío J, Zarco P, Linares L, Collantes E, Fernández-Barrial M, Hermosa J, Coto P, Suárez C, Almodόvar R, Luelmo J, Cárcaba V, Castañeda S, Otόn T, Curbelo R, Gratacόs J. FRI0458 Assessment of Comorbidity in Psoriatic Disease: How Often Should Be Performed?: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Moreno-Ramírez D, Ruiz-Villaverde R, de Troya M, Reyes-Alcázar V, Alcalde M, Galán M, García-Lora E, García E, Linares M, Martínez-Pilar L, Pulpillo Á, Suárez C, Vélez A, Torres A. Process of Care for Patients With Benign Cysts and Tumors: Consensus Document of the Andalusian Regional Section of the Spanish Academy of Dermatology and Venereology (AEDV). Actas Dermo-Sifiliográficas (English Edition) 2016. [DOI: 10.1016/j.adengl.2016.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
32
|
Moreno-Ramírez D, Ruiz-Villaverde R, de Troya M, Reyes-Alcázar V, Alcalde M, Galán M, García-Lora E, García EI, Linares M, Martínez L, Pulpillo Á, Suárez C, Vélez A, Torres A. Process of Care for Patients With Benign Cysts and Tumors: Consensus Document of the Andalusian Regional Section of the Spanish Academy of Dermatology and Venereology (AEDV). Actas Dermosifiliogr 2016; 107:391-9. [PMID: 26826882 DOI: 10.1016/j.ad.2015.10.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2015] [Revised: 10/25/2015] [Accepted: 10/29/2015] [Indexed: 11/30/2022] Open
Abstract
Benign skin lesions are a common reason for visits to primary care physicians and dermatologists. However, access to diagnosis and treatment for these lesions varies considerably between users, primarily because no explicit or standardized criteria for dealing with these patients have been defined. Principally with a view to reducing this variability in the care of patients with benign cysts or tumors, the Andalusian Regional Section of the Spanish Academy of Dermatology and Venereology (AEDV) has created a Process of Care document that describes a clinical pathway and quality-of-care characteristics for each action. This report also makes recommendations for decision-making with respect to lesions of this type.
Collapse
Affiliation(s)
- D Moreno-Ramírez
- Unidad de Gestión Clínica de Dermatología MQyV, Hospital Universitario Virgen Macarena, Sevilla, España
| | - R Ruiz-Villaverde
- Unidad de Gestión Clínica de Dermatología MQyV, Hospital Universitario Virgen de las Nieves, Granada, España
| | - M de Troya
- Unidad de Gestión Clínica de Dermatología MQyV, Hospital Costa del Sol, Marbella, España
| | | | - M Alcalde
- Unidad de Gestión Clínica de Dermatología MQyV, Hospital Torrecárdenas, Almería, España
| | - M Galán
- Unidad de Gestión Clínica de Dermatología MQyV, Complejo Hospitalario de Jaén, Jaén, España
| | - E García-Lora
- Unidad de Gestión Clínica de Dermatología MQyV, Hospital Universitario Virgen de las Nieves, Granada, España
| | - E I García
- Facultad de Enfermería, Universidad de Cádiz, Cádiz, España
| | - M Linares
- Unidad de Gestión Clínica de Dermatología MQyV, Hospital Universitario Puerta del Mar, Cádiz, España
| | - L Martínez
- Unidad de Gestión Clínica de Dermatología MQyV, Hospital Regional de Málaga, Málaga, España
| | - Á Pulpillo
- Unidad de Gestión Clínica de Dermatología MQyV, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - C Suárez
- Unidad de Gestión Clínica de Dermatología MQyV, Complejo Hospitalario de Huelva, Huelva, España
| | - A Vélez
- Unidad de Gestión Clínica de Dermatología MQyV, Hospital Universitario Reina Sofía, Córdoba, España
| | - A Torres
- Agencia de Calidad Sanitaria de Andalucía, Sevilla, España.
| |
Collapse
|
33
|
Ruiz-Villaverde R, Moreno-Ramírez D, Galán-Gutierrez M, de Troya M, Reyes-Alcázar V, Alcalde M, García EI, Linares M, Martínez L, Pulpillo Á, Suárez C, Vélez A, García-Lora E, Torres A. Clinical Pathway for Patients with Acute or Chronic Urticaria: A Consensus Statement of the Andalusian Section of the Spanish Academy of Dermatology and Venereology (AEDV). Actas Dermosifiliogr 2016; 107:482-8. [PMID: 26803228 DOI: 10.1016/j.ad.2015.11.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Revised: 11/16/2015] [Accepted: 11/21/2015] [Indexed: 10/22/2022] Open
Abstract
Attention has been focused on new ways to understand and manage urticaria ever since the recent addition of novel drugs to the therapeutic arsenal, the updating of clinical practice guidelines, and the publication of pathophysiologic insights. The Andalusian Section of the Spanish Academy of Dermatology and Venereology (AEDV) has developed a clinical pathway that defines quality-of-care characteristics and makes recommendations on decision-making affecting patients with urticaria. We present a patient-centered approach to care, in which the patient's clinical pathway through the health care system includes links between primary and hospital care to ensure continuity-a key feature of quality.
Collapse
Affiliation(s)
- R Ruiz-Villaverde
- Unidad de Gestión Clínica de Dermatología Médico-quirúrgica y Venereología, Hospital Universitario Virgen de las Nieves, Granada, España.
| | - D Moreno-Ramírez
- Unidad de Gestión Clínica de Dermatología Médico-quirúrgica y Venereología, Hospital Universitario Virgen Macarena, Sevilla, España
| | - M Galán-Gutierrez
- Unidad de Gestión Clínica de Dermatología Médico-quirúrgica y Venereología, Complejo Hospitalario de Jaén, Jaén, España
| | - M de Troya
- Unidad de Gestión Clínica de Dermatología Médico-quirúrgica y Venereología, Hospital Costa del Sol, Marbella, España
| | | | - M Alcalde
- Unidad de Gestión Clínica de Dermatología Médico-quirúrgica y Venereología, Hospital Torrecárdenas, Almería, España
| | - E I García
- Facultad de Enfermería, Universidad de Cádiz, Cádiz, España
| | - M Linares
- Unidad de Gestión Clínica de Dermatología Médico-quirúrgica y Venereología, Hospital Universitario Puerta del Mar, Cádiz, España
| | - L Martínez
- Unidad de Gestión Clínica de Dermatología Médico-quirúrgica y Venereología, Hospital Regional de Málaga, Málaga, España
| | - Á Pulpillo
- Unidad de Gestión Clínica de Dermatología Médico-quirúrgica y Venereología, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - C Suárez
- Unidad de Gestión Clínica de Dermatología Médico-quirúrgica y Venereología, Complejo Hospitalario de Huelva, Huelva, España
| | - A Vélez
- Unidad de Gestión Clínica de Dermatología Médico-quirúrgica y Venereología, Hospital Universitario Reina Sofía, Córdoba, España
| | - E García-Lora
- Unidad de Gestión Clínica de Dermatología Médico-quirúrgica y Venereología, Hospital Universitario Virgen de las Nieves, Granada, España
| | - A Torres
- Agencia de Calidad Sanitaria de Andalucía, Sevilla, España
| |
Collapse
|
34
|
Olaiz N, Signori E, Maglietti F, Soba A, Suárez C, Turjanski P, Michinski S, Marshall G. Tissue damage modeling in gene electrotransfer: The role of pH. Bioelectrochemistry 2014; 100:105-11. [DOI: 10.1016/j.bioelechem.2014.05.001] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2013] [Revised: 04/22/2014] [Accepted: 05/02/2014] [Indexed: 02/05/2023]
|
35
|
Pelegrín I, Moragas M, Suárez C, Ribera A, Verdaguer R, Martínez-Yelamos S, Rubio-Borrego F, Ariza J, Viladrich PF, Cabellos C. Listeria monocytogenes meningoencephalitis in adults: analysis of factors related to unfavourable outcome. Infection 2014; 42:817-27. [DOI: 10.1007/s15010-014-0636-y] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2013] [Accepted: 05/19/2014] [Indexed: 01/25/2023]
|
36
|
Suárez C, Antonarakis GS, Pham D. Occlusal characteristics in subjects with or without the ability to roll the tongue. Eur J Paediatr Dent 2014; 15:147-150. [PMID: 25102465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM The tongue represents an important intraoral muscular force which is in direct contact with the dental arches. The objective of the current study was to compare occlusal characteristics of patients who have the ability to roll their tongue (TR+) to those who cannot (TR-). MATERIALS AND METHODS A hundred consecutive patients under orthodontic treatment were classified as TR+ (n=73) or TR- (n=27). Pre-treatment orthodontic study casts were used to measure intercanine and intermolar widths, arch lengths, space deficiency, overjet, overbite, presence or absence of posterior crossbite and the molar Angle class. For continuous variables, independent sample t-tests and Mann-Whitney U tests were used to examine differences between the groups. For dichotomous variables, chi-square tests were used to examine differences between groups. RESULTS TR+ patients showed larger mandibular inter-molar widths (1 mm, p<0.05) and less mandibular space deficiency (1.9 mm, p<0.05) than TR- patients. Mandibular space deficiency was present in the mandibular arch in 18.5% of TR+ compared to 49.3% in TR- patients (p<0.05). CONCLUSION The ability to roll the tongue may lead to differences in occlusal characteristics, namely an increase in mandibular intermolar width and a less mandibular space deficiency.
Collapse
Affiliation(s)
- C Suárez
- Department of Orthodontics and Pediatric Dentistry, University of Geneva Dental School, Switzerland
| | - G S Antonarakis
- Department of Orthodontics and Pediatric Dentistry, University of Geneva Dental School, Switzerland
| | - D Pham
- Department of Orthodontics and Pediatric Dentistry, University of Geneva Dental School, Switzerland
| |
Collapse
|
37
|
Grande M, Rodríguez P, Terol M, Triviño M, Suárez C, Gil C. P239: Salmonella group B 4,5 outbreak on a neonatology unit. Antimicrob Resist Infect Control 2013. [PMCID: PMC3687740 DOI: 10.1186/2047-2994-2-s1-p239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
38
|
Morales-Barrera R, Suárez C, Valverde C, Nuñez I, Maldonado X, Morote J, Carles J. Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy? Clin Transl Oncol 2013; 16:102-6. [DOI: 10.1007/s12094-013-1045-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2012] [Accepted: 04/08/2013] [Indexed: 11/28/2022]
|
39
|
Real de Asúa D, Suárez C. Diferencias y similitudes entre los bloqueadores de los receptores del calcio (antagonistas del calcio). Hipertensión y Riesgo Vascular 2013. [DOI: 10.1016/s1889-1837(13)70022-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
40
|
García-Fernández R, García-Palencia P, Suárez C, Sánchez M, Sánchez B, Martín-Caballero J, y Flores J. Interaction between p21cip1/waf1 and p27kip1 in Cellular Senescence in Tumours. J Comp Pathol 2013. [DOI: 10.1016/j.jcpa.2012.11.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
41
|
Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco A, Aguilar M, Ferrándiz C, Puig L, Sánchez-Carazo J. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 2012; 27:1387-404. [DOI: 10.1111/jdv.12024] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
42
|
Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, Bonilla C, Jave O, Contreras CC, Atwood S, Blaya JA, Ershova J, Cegielski JP. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis 2012; 16:1538-43. [PMID: 22990138 DOI: 10.5588/ijtld.12.0071] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
SETTING Programmatic implementation of decentralized rapid drug susceptibility testing (DST) in Lima, Peru. OBJECTIVE Pre-post analysis compared time to diagnosis, treatment outcome and survival among patients tested with direct nitrate reductase assay (NRA) vs. indirect conventional methods. DESIGN From 2005 to 2009, we prospectively followed all patients referred for DST before (control) and after (intervention) NRA implementation. Among those referred for DST, NRA was used for smear-positive samples of patients with no prior history of multidrug resistance or treatment for multidrug-resistant tuberculosis (TB). Data were abstracted from patient charts and laboratory registers. Endpoints were favorable outcomes, time to result and time to death. RESULTS Of those patients who met the criteria for NRA, 740 underwent NRA and 621 underwent conventional DST. NRA yielded test results for 78.4% of cases vs. 68.8% for conventional DST (P < 0.0001); the median time to result was 44 vs. 133 days, respectively (adjusted HR 0.64, 95%CI 0.56-0.73). Among individuals without previous anti-tuberculosis treatment, NRA was associated with a favorable treatment outcome (adjusted OR 1.39, 95%CI 1.01-1.90) and prolonged survival (adjusted HR 0.53, 95%CI 0.31-0.90). CONCLUSION Direct NRA significantly shortened time to test result and improved treatment outcomes and survival in certain groups.
Collapse
Affiliation(s)
- S S Shin
- Division of Global Health Equity, and Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Suárez C, Castro AJ, Rapoport HF, Rodríguez-García MI. Morphological, histological and ultrastructural changes in the olive pistil during flowering. ACTA ACUST UNITED AC 2012; 25:133-46. [DOI: 10.1007/s00497-012-0186-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2011] [Accepted: 03/16/2012] [Indexed: 11/24/2022]
|
44
|
Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco A, Aguilar M, Ferrándiz C, Puig L, Sánchez-Carazo J. Abordaje integral de la comorbilidad del paciente con psoriasis. Actas Dermo-Sifiliográficas 2012; 103 Suppl 1:1-64. [DOI: 10.1016/s0001-7310(12)70001-7] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
45
|
Gasch O, Hornero A, Domínguez MA, Fernández A, Suárez C, Gómez S, Camoez M, Linares J, Ariza J, Pujol M. Methicillin-susceptible Staphylococcus aureus clone related to the early pandemic phage type 80/81 causing an outbreak among residents of three occupational centres in Barcelona, Spain. Clin Microbiol Infect 2011; 18:662-7. [PMID: 21973164 DOI: 10.1111/j.1469-0691.2011.03663.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In the 1950s an unusually virulent and transmissible penicillin-resistant Staphylococcus aureus clone harbouring Panton-Valentine leukocidin (PVL) genes, known as phage type 80/81 and subsequently identified as multilocus sequence type (ST) 30, emerged and caused serious infections in hospitals and the community. We describe an outbreak of skin infections caused by a PVL-positive, methicillin-susceptible S. aureus (MSSA) strain of ST1472, related to phage type 80/81, in three associated occupational centres. After identification of the first patient an active case-finding strategy was initiated among the three centres. Epidemiological and clinical features were indistinguishable from outbreaks currently caused by community-acquired methicillin-resistant S. aureus. The S. aureus was cultured and identified from nasal swabs and skin lesions by conventional methods; PVL was detected using a PCR assay. Pulsed-field gel electrophoresis and DNA-array-based genotyping were applied to MSSA isolates. MSSA was identified in nasal swabs from 49 of 133 individuals (37%). A single pulsed-field gel electrophoresis pattern, belonging to ST1472 (CC30) and PVL positivity, were detected in 20 individuals, including eight of 18 skin cultures, i.e. 15% of the screened individuals were colonized by the epidemic strain. Nasal and cutaneous decontamination with 5% nasal mupirocin ointment and 2% aqueous chlorhexidine was implemented for all individuals. Patients with active skin infections were treated with a first-generation cephalosporin. General recommendations were made to prevent cross-transmission. No new cases were reported over the following 90 days.
Collapse
Affiliation(s)
- O Gasch
- Department of Infectious Diseases, IDIBELL, Hospital Universitari de Bellvitge, Universitat de Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Barrera RM, Suárez C, Nunez I, Valverde C, Serrano C, Fernandez OC, Garcia-Corbacho J, Raventos C, Maldonado X, Carles J. 7129 POSTER Adjuvant Chemotherapy for High-risk Patients With Urothelial Carcinoma. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72044-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
47
|
Puchades R, Rodríguez F, Gabriel R, Suárez C. Prevalencia de insuficiencia renal en ancianos. Rev Clin Esp 2011; 211:221-2. [DOI: 10.1016/j.rce.2010.10.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2010] [Revised: 09/30/2010] [Accepted: 10/04/2010] [Indexed: 01/17/2023]
|
48
|
Pérez-Rama M, Torres E, Suárez C, Herrero C, Abalde J. Sorption isotherm studies of Cd(II) ions using living cells of the marine microalga Tetraselmis suecica (Kylin) Butch. J Environ Manage 2010; 91:2045-2050. [PMID: 20573442 DOI: 10.1016/j.jenvman.2010.05.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/06/2009] [Revised: 04/26/2010] [Accepted: 05/14/2010] [Indexed: 05/29/2023]
Abstract
The present work reports the use of living cells of the marine microalga Tetraselmis suecica for the biosorption of cadmium ions. For a better understanding of the biosorption characteristics, three fractions of removed cadmium (total, bioadsorbed and intracellular) were measured in the cells after 24 and 72 h of exposure to different initial cadmium concentrations (0.6-45 mg L(-1)). Both the Langmuir and Freundlich models were suitable for describing the sorption of cadmium ions by this microalga. The maximum sorption capacity was estimated to be 40.22 mg Cd g(-1) after 72 h using the Langmuir sorption model. In the lower cadmium concentrations, metal removed intracellularly was higher than that removed on the microalgal cell surface. Therefore, the intracellular fraction contributed more to the total removed cadmium than the fraction bioadsorbed to the cellular surface. The results showed that the cadmium removal capacity using living biomass could be much more effective than with non-living biomass due to the intracellular bioaccumulation. According to the microorganism selected and its tolerance to the toxic effect of the metal, the cadmium content in the intracellular fraction can become very significant, just like it happened with Tetraselmis.
Collapse
Affiliation(s)
- M Pérez-Rama
- Departamento de Biología Celular y Molecular, Laboratorio de Microbiología, Facultad de Ciencias, Universidade da Coruña, Alejandro de la Sota n degrees 1, 15008 La Coruña, Spain
| | | | | | | | | |
Collapse
|
49
|
Olaiz N, Maglietti F, Suárez C, Molina F, Miklavcic D, Mir L, Marshall G. Electrochemical treatment of tumors using a one-probe two-electrode device. Electrochim Acta 2010. [DOI: 10.1016/j.electacta.2010.05.057] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
50
|
Alvarez Alija G, Menéndez S, García-Carracedo D, Allonca E, Mancebo G, Suárez C, Rodrigo J, García-Pedrero J. 155 Clinical significance of the expression and amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70963-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|